Medtronic Reveals Beacon Heart Failure Management Service
Medtronic plc (NYSE: MDT) revealed its Beacon Heart Failure Management Service is available in the United States. According to the company, this new service from Medtronic Care Management Services (MCMS) integrates data from its implantable cardioverter defibrillator (ICD) or cardiac resynchronization therapy (CRT) devices with post-acute monitoring from MCMS. That allow providers to focus on heart failure patients with the greatest risk and assess early intervention before a heart failure event happens.
Medtronic's VP and GM for its MCMS, Sheri Dodd, said, "Healthcare systems are under increasing pressure to improve patient care while also driving down associated cost. MCMS is committed to helping our customers deliver better patient outcomes while addressing these challenges."
Dodd added, "Our technologies - and the data and insights they generate - put us in a unique position to help our customers enhance their patient care. With its combination of implanted device diagnostics, daily monitoring, and qualified expertise, Beacon is just one way Medtronic is innovating to provide clinically-meaningful services to hospitals, physicians, patients, and payers."
The company indicated Beacon combines device diagnostics, expert analysis, and proprietary remote monitoring solutions from MCMS to generate an improved picture of a patient's health. The medical equipment maker added that patients using Beacon engage in daily health checks. The company believes that it not only educate patients about their condition and self-care, but also collect symptoms and biometrics through a series of branching-logic questions.
Medtronic said this data was assembled along with diagnostics from the patient's ICD or CRT device and reviewed by appropriately certified Medtronic care managers. Its managers follow established clinical pathways to review incoming data, scrutinize for information that could indicate a growing risk of a heart failure event and alert providers accordingly.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.